4//SEC Filing
BENET LESLIE Z 4
Accession 0001003642-18-000084
CIK 0001003642other
Filed
May 7, 8:00 PM ET
Accepted
May 8, 4:20 PM ET
Size
29.9 KB
Accession
0001003642-18-000084
Insider Transaction Report
Form 4
BENET LESLIE Z
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−12,000→ 0 totalExercise: $44.85Exp: 2025-05-12→ Common Stock (12,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−19,600→ 0 totalExercise: $25.24Exp: 2024-05-14→ Common Stock (19,600 underlying) - Disposition to Issuer
Common Stock
2018-05-04−17,741→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−10,575→ 0 totalExercise: $16.40Exp: 2027-05-16→ Common Stock (10,575 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−25,000→ 0 totalExercise: $17.99Exp: 2023-05-15→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−16,000→ 0 totalExercise: $20.90Exp: 2022-05-23→ Common Stock (16,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−19,000→ 0 totalExercise: $27.97Exp: 2021-05-11→ Common Stock (19,000 underlying) - Disposition to Issuer
Restricted Common Stock
2018-05-04−4,742→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−2,750→ 0 totalExercise: $35.89Exp: 2020-01-09→ Common Stock (2,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−19,000→ 0 totalExercise: $20.30Exp: 2020-05-26→ Common Stock (19,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−30,000→ 0 totalExercise: $6.55Exp: 2019-05-20→ Common Stock (30,000 underlying) - Disposition to Issuer
Common Stock
2018-05-04−600→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−10,575→ 0 totalExercise: $30.33Exp: 2026-05-17→ Common Stock (10,575 underlying)
Footnotes (3)
- [F1]Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
- [F2]Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock.
- [F3]Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Documents
Issuer
Impax Laboratories, LLC
CIK 0001003642
Entity typeother
Related Parties
1- filerCIK 0001245186
Filing Metadata
- Form type
- 4
- Filed
- May 7, 8:00 PM ET
- Accepted
- May 8, 4:20 PM ET
- Size
- 29.9 KB